.beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use
CA 2248971 A1 · Owner: Kyowa Hakko Kirin Co. Ltd. · Inventors: Fukuda, Minoru; Sekine, Susumu; Miura, Kazumi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides pharmaceutical preparations for anti-inflammation, anti-infection inhibition of cancer metastasis etc. foods such as dairy products etc. and a method for improving proteins as well as, a method for diagnosis of inflammatory diseases and cancer malignancy. According to the present invention there can be, provided a polypeptide having poly-N-acetyllactosamine sugar chains synthesis-related activity, a process for producing the polypeptide, DNA coding for the polypeptide a process for, producing the DNA, a recombinant vector having the DNA integrated therein, a transformant carrying the recombinant vector, an antibody recognizing the polypeptide a process for, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 27, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 27, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 27, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.